Technology company Echo IQ (ASX:EIQ) started the integration of its EchoSolv-AS decision support software with Beth Israel Deaconess Medical Center in the US, according to a Monday filing with the Australian bourse.
EchoSolv-AS is used to assess severe aortic stenosis, a condition where the heart's aortic valve is narrowed or blocked, causing blood to have difficulty passing through.
The integration follows a trial of EchoSolv-AS by Beth Israel researchers on a group of 31,000 patients, according to the filing.
Echo IQ shares rose past 11% in afternoon trade Monday.
Price (AUD): $0.25, Change: $+0.03, Percent Change: +11.11%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.